Monthly Archives: July 2020

Genetics

Generational Equity Advises New Generation Genetics in its Sale to Swissgenetics International – Business Wire

DALLAS--(BUSINESS WIRE)--Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, New Generation Genetics to Swissgenetics International. The acquisition closed July 1, 2020 and details were not disclosed.

New Generation Genetics (NGG), located in Fort Atkinson, Wisconsin, has a primary goal of providing its customers with the best Brown Swiss genetics in the industry. NGG focuses solely on Brown Swiss, giving them the advantage over their competitors. The Company has over 50 years of Brown Swiss A.I. experience combined. They currently offer top bulls for Milk, Type, Net Merit, Sire Conception Rate (SCR), Fat, Protein, and PPR Index. They currently sample only the top genomic bulls and continue to lead the breed by sampling 12 young bulls per year.

Swissgenetics International is located in Zollikofen, Switzerland. Successful milk and beef producers rely on sustainable breeding strategies and professional production methods. To achieve this, high-performance and healthy animals are needed. The genetics programs from Swissgenetics are aligned consistently to meet and exceed these requirements. Through the testing programs operated in partnership with breeders and breeding organizations, marketable and future-oriented genetics are developed at an international level. Beneficial breeding cooperation assumes mutual trust between genetics providers and breeders. This requires high levels of competence and transparency on both sides. Swissgenetics is a leader in this field.

Generational Equity Executive Managing Director of M&A Central Region, Michael Goss, and his team lead by Managing Director Mergers & Acquisitions, Stephen Dinehart, with support from Managing Director Mergers & Acquisition, Ryan Johnson, successfully closed the deal. Senior Managing Director Joe Van Voorhis established the initial relationship with NGG.

This is a great acquisition for the Brown Swiss producer family combining two of the major players in Brown Swiss Genetics, said Dinehart. It is a win for both the customers and employees of Swissgenetics and NGG.

About Generational Equity

Generational Equity, Generational Capital Markets (member FINRA/SIPC), Generational Wealth Advisors, Generational Consulting Group, and DealForce are part of the Generational Group, which is headquartered in Dallas and is one of the leading M&A advisory firms in North America.

With over 250 professionals located throughout North America, the companies help business owners release the wealth of their business by providing growth consulting, merger, acquisition, and wealth management services. Their six-step approach features strategic and tactical growth consulting, exit planning education, business valuation, value enhancement strategies, M&A transactional services, and wealth management.

The M&A Advisor named the company the 2016, 2017, and 2018 Investment Banking Firm of the Year. For more information, visit https://www.genequityco.com/ or the Generational Equity press room.

Go here to see the original:
Generational Equity Advises New Generation Genetics in its Sale to Swissgenetics International - Business Wire

Genetics

Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? – The New Economy

Embryonic stem cells. The ethical issues associated with stem cell research could be resolved through the use of induced pluripotent stem cells, which are derived from fully committed and differentiated cells of the adult body

The almost miraculous benefits that stem cells may one day deliver have long been speculated on. Capable of becoming different types of cells, they offer huge promise in terms of transplant and regenerative medicine. It is, however, also a medical field that urges caution one that must constantly battle exaggeration. If stem cells do in fact hold the potential to reverse the ageing process, for example, then such breakthroughs remain many years away.

Recently, though, the field has had cause for excitement. In 2006, Japanese researcher Shinya Yamanaka discovered that mature cells could be reprogrammed to become pluripotent, meaning they can give rise to any cell type of the body. In 2012, the discovery of these induced pluripotent stem cells (iPSCs) saw Yamanaka and British biologist John Gurdon awarded the Nobel Prize in Physiology or Medicine. Since then, there has been much talk regarding the potential iPSCs possess, not only for the world of medicine, but for society more generally, too.

A big stepHistorically, one of the major hurdles preventing further research into stem cells has been an ethical one. Until the discovery of iPSCs, embryonic stem cells (ESCs) represented the predominant area of research, with cells being taken from preimplantation human embryos. This process, however, involves the destruction of the embryo and, therefore, prevents the development of human life. Due to differences in opinion over when life is said to begin during embryonic development, stem cell researchers face an ethical quandary.

The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals

With iPSCs, though, no such dilemmas exist. IPSCs are almost identical to ESCs but are derived from fully committed and differentiated cells of the adult body, such as a skin cell. Like ESCs, iPSCs are pluripotent and, as they are stem cells, can self-renew and differentiate, remaining indefinitely propagated and retaining the ability to give rise to any human cell type over time.

One important distinction to make is that both ESCs and iPSCs do not exist in nature, Vittorio Sebastiano, Assistant Professor (Research) of Obstetrics and Gynaecology (Reproductive and Stem Cell Biology) at Stanford Universitys Institute for Stem Cell Biology and Regenerative Medicine, told The New Economy. They are both beautiful laboratory artefacts. This means that at any stage of development, you cannot find ESCs or iPSCs in the developing embryo, foetus or even in the postnatal or adult body. Both ESCs and iPSCs can only be established and propagated in the test tube.

The reason neither ESCs nor iPSCs can be found in the body is that they harbour the potential to be very dangerous. As Sebastiano explained, these cells could spontaneously differentiate into tumorigenic masses because of their intrinsic ability to give rise to any cell type of the body. Over many years of research, scientists have learned how to isolate parts of the embryo (in the case of ESCs) and apply certain culture conditions that can lock cells in their proliferative and stem conditions. The same is true for iPSCs.

To create iPSCs, scientists take adult cells and exogenously provide a cocktail of embryonic factors, known as Yamanaka factors, for a period of two to three weeks. If the expression of such factors is sustained for long enough, they can reset the programme of the adult cells and establish an embryonic-like programme.

Turning back the clockThere is already a significant body of research dedicated to how stem cells can be used to treat disease. For example, mesenchymal stem cells (usually taken from adult bone marrow) have been deployed to treat bone fractures or as treatments for autoimmune diseases. It is hoped that iPSCs could hold the key for many more treatments.

Global stem cell market:25.5%Expected compound annual growth rate (2018-24)$467bnExpected market value (2024)

IPSCs are currently utilised to model diseases in vitro for drug screening and to develop therapies that one day will be implemented in people, Sebastiano explained. Given their ability to differentiate into any cell type, iPSCs can be used to differentiate into, for example, neurons or cardiac cells, and study specific diseases. In addition, once differentiated they can be used to test drugs on the relevant cell type. Some groups and companies are developing platforms for cell therapy, and I am personally involved in two projects that will soon reach the clinical stage.

Perhaps the most exciting prospects draw on iPSCs regenerative properties. Over time, cells age for a variety of reasons namely, increased oxidative stress, inflammation and exposure to pollutants or sunlight, among others. All these inputs lead to an accumulation of epigenetic mistakes those that relate to gene expression rather than an alteration of the genetic code itself in the cells, which, over time, results in the aberrant expression of genes, dysfunctionality at different levels, reduced mitochondrial activity, senescence and more besides. Although the epigenetic changes that occur with time may not be the primary cause of ageing, the epigenetic landscape ultimately affects and controls cell functionality.

What we have shown is that, if instead of being expressed for two weeks we express the reprogramming factors for a very short time, then we see that the cells rejuvenate without changing their identity, Sebastiano said. In other words, if you take a skin cell and express the reprogramming genes for two to four days, what you get is a younger skin cell.

By reprogramming a cell into an iPSC, you end up with an embryonic-like cell the reprogramming erases any epigenetic errors. If expressed long enough, it erases the epigenetic information of cell identity, leaving embryonic-like cells that are also young.

Slow and steadyAs with any scientific advancement, financial matters are key. According to Market Research Engine, the global stem cell market is expected to grow at a compound annual growth rate of 25.5 percent between 2018 and 2024, eventually reaching a market value of $467bn. The emergence of iPSCs has played a significant role in shaping these predictions, with major bioscience players, such as Australias Mesoblast and the US Celgene, working on treatments involving this particular type of stem cell.

The business potential around stem cell research is huge, Sebastiano told The New Economy. [Particularly] when it comes to developing cell banks for which we have detailed genetic information and, for example, studying how different drugs are toxic or not on certain genetic backgrounds, or when specific susceptibility mutations are present.

Unfortunately, even as the business cases for iPSC treatments increase, a certain degree of caution must be maintained. The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals. There have been numerous reports of complications emerging, including the formation of a tumour following experimental stem cell treatment in one particular patient, as recorded in the Canadian Medical Association Journal last year. Such failures risk setting the field back years.

The challenge for researchers now will be one of balance. The potential of iPSCs is huge both in terms of medical progress and business development but can easily be undermined by misuse. Medical advancements, particularly ones as profound as those associated with iPSCs, simply cannot be rushed.

Go here to read the rest:
Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? - The New Economy

Genetics

Genetics company adds COVID-19 testing to services – Business Times of Western Colorado

About Wordfence

Wordfence is a security plugin installed on over 3 million WordPress sites. The owner of this site is using Wordfence to manage access to their site.

You can also read the documentation to learn about Wordfence's blocking tools, or visit wordfence.com to learn more about Wordfence.

Read the rest here:
Genetics company adds COVID-19 testing to services - Business Times of Western Colorado

Genetics

Predictive Genetic Testing and Consumer/Wellness Genomics Market Analytical Overview and Size(Value and Volume) by 2025 – Cole of Duty

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Here is the original post:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Analytical Overview and Size(Value and Volume) by 2025 - Cole of Duty

Genetics

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 – Yahoo Finance

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

Thursday, July 30, 20201:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the Companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSATM (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005173/en/

Contacts

Investors Peggy Pinkston(425) 527-4160ppinkston@seagen.com

Media Monique Greer(425) 527-4641mgreer@seagen.com

Read more from the original source:
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 - Yahoo Finance

Neuroscience

Kernel raises $53M to expand access to its Neuroscience as a Service platform – VatorNews

The company was founded by Braintree's Bryan Johnson

Kernelis a company pioneering a new space:Neuroscience as a Service (NaaS), in which it noninvasively records brain activity, allowing its customers to measure and quantify cognition on-demand.

It's a fairly new technology, and it's caught the interest of investors, who just poured $53 million into the company, it was announced on Thursday. The round was led by General Catalyst, with participation from Khosla Ventures, Eldridge, Manta Ray Ventures, Tiny Blue Dot and Bryan Johnson, founder and CEO of Kernel.

While this is being called a Series C round, it's actually the first outside funding the company has taken; until now, it had raised $54 million, all from Johnson's own pocket, bringing its total funding to $107 million. Johnson was previously the founder, chairman and CEO of payment company Braintree, which was acquired by eBay for $800 million in 2013.

Founded in 2016, Kernel's platform is powered by two brain recording technologies: one is called "Flux," which is short for "magnetic flux." It detects the magnetic fields generated by collective neural activity in the brain. The other is called "Flow," short for "blood flow," and it detects cortical hemodynamics, which is representative of neural activity.

Kernel's customers can use the technology to do things such as explore biomarkers, but the company is also getting a lot of interest from customers trying to use it for improving machine learning algorithms for such applications as image recognition and voice recognition.

One group that Kernel is working with, for example, is trying to quantify a neural assessment, instead of relying on qualitative questions and self-reporting.Another company is using the neural data to improve image recognition algorithms; Kernal is able to provide vast amounts of brain data that can be fed to a deep neural network for a much higher representation of an image.

Along with the funding, it was revealed that Quentin Clark, Managing Director at General Catalyst, has joined the Board of Directors at Kernel.

"The vision fueling Kernel is one of the most audacious imaginable." Clark said in a statement. "But that ambition has a passionate and committed founder and team, and pragmatic engineering work to back it up. Kernel's engineering accomplishments have the potential to enable more neuroscience progress in the next few years than has been accomplished in the last few decades."

Read more:
Kernel raises $53M to expand access to its Neuroscience as a Service platform - VatorNews

Neuroscience

Neuroscience Antibodies & Assays Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 – 3rd Watch News

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Neuroscience Antibodies & Assays Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Neuroscience Antibodies & Assays market.

The research study includes the latest updates about the COVID-19 impact on the Neuroscience Antibodies & Assays sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Neuroscience Antibodies & Assays manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Neuroscience Antibodies & Assays market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Neuroscience Antibodies & Assays sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Neuroscience Antibodies & Assays, the report covers-

Bytype1

In Market Segmentation by Applications of the Neuroscience Antibodies & Assays, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=28342&utm_source=3WN&utm_medium=003

The Neuroscience Antibodies & Assays market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Neuroscience Antibodies & Assays market.

This study analyzes the growth of Neuroscience Antibodies & Assays based on the present, past and futuristic data and will render complete information about the Neuroscience Antibodies & Assays industry to the market-leading industry players that will guide the direction of the Neuroscience Antibodies & Assays market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Neuroscience Antibodies & Assays market. Additionally, it includes a share of each segment of the Neuroscience Antibodies & Assays market, giving methodical information about types and applications of the market.

Reasons for Buying Neuroscience Antibodies & Assays Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Neuroscience Antibodies & Assays market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Neuroscience-Antibodies-&-Assays-Market/?utm_source=3WN&utm_medium=003

In the end, the Neuroscience Antibodies & Assays market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Neuroscience Antibodies & Assays market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Follow this link:
Neuroscience Antibodies & Assays Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

Neuroscience

BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from…

Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation

NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the Company has initiated an expanded access program at Massachusetts General Hospital (MGH) to provide its investigational drug, BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), to critically ill patients diagnosed with COVID-19 in the intensive care unit ("ICU") that may require calming or arousable sedation.

We are pleased to support clinicians at MGH as they manage an in-flux of COVID-19 patients, commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI. COVID-19 primarily affects the respiratory system, with the severely ill often requiring mechanical ventilation. As a result of critical illness and the medical coma that is necessary for mechanical ventilation, patients frequently develop delirium and agitation, causing worse clinical outcomes and extended hospital stays. BXCL501 is being studied in advanced clinical trials to treat acute agitation, and we believe it has the potential, if approved, to help physicians treat patients that may be struggling with agitation or delirium.

Facilitated by the U.S. Food and Drug Administration (FDA), expanded access, also known as compassionate use, provides an opportunity for patients to receive an investigational treatment prior to regulatory approval when there are no comparable or satisfactory therapeutic alternatives available.

Being on the frontlines of this pandemic, our intensivists have witnessed firsthand the high numbers of critically ill patients diagnosed with COVID-19 and ICU delirium, added Seun Johnson-Akeju, M.D., M.M.Sc., Anesthetist-in-Chief of the Department of Anesthesia, Critical Care and Pain Medicine at the Massachusetts General Hospital. The COVID-19 surge caused an acute shortage of medications for managing agitation. We are hopeful that BXCL501 will improve the clinical outcomes of critically ill patients diagnosed with COVID-19 that are struggling with agitation and ICU delirium.

About BXCL501

BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in the Phase 1b/2 TRANQUILITY trial for the treatment of agitation associated with dementia, as well as the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the evaluation of the Companys investigational drug, BXCL501, in the treatment of COVID-19 patients. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by its Current Report on Form 8-K filed on April 14, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and the Investors page of its website atwww.bioxceltherapeutics.com.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

Contact Information:BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

More here:
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from...

Neuroscience

I Chose Protesting for Black Lives Matter Over Writing My PhD Dissertation – Union of Concerned Scientists

These past few weeks,Ivehad to make a choice between writing my doctoral dissertation and protesting for the safety and protection of Black Lives. I chose the latter.

I began my PhD program in July of 2016, a few weeks after the deaths ofPhilando CastileandAlton Sterlingwho were both murdered by police officers. Not too long after, I attended my first graduate program retreat, which happened to be at an African American History museum. During the retreat, I felt more secluded in my Blackness as I noticed that many of my peers did not understand that we are still living through many of the same racial injustices depicted in the museum. A desensitizationin regards tothese instances that seem so long ago to White people, but have impacted me for 26 years of my life. I felt traumatized again by the history of my ancestors and plagued with the current police killings of innocent Black Americans today.

This is just one example of many such experiences throughout my PhD program.

We are currently living in the digital age of police brutality where incidents of unarmed Black people have been recorded for social media viewing. As a Neuroscience Doctoral Candidate, I have been expected to remain productive by analyzing and collecting data. However, as a Black woman I have also had to deal with conflicting perspectives on how I am expected to proceed when I am emotionallyexhaustedand my mental health is suffering. I inherited the sorrows of my ancestors as I have been filled with grief over the most recent murders ofGeorge Floyd,Breonna Taylor,AhmaudArbery,Tony McDade, andSean Reed. I have not been afforded the luxury of ignoring these incidents as systemic racism chokes the air that I breathe.

My non-Black peers and professors are finally attempting to understand my experience as a Black woman scientist. However, what needs to be understood is that systemic racism is embedded in the history of science and is still present today. In 2017, I organized a workshop on Microaggressions in STEM as a way for graduate students and faculty to understand their own unconscious biases. A few days before the event, someone RSVPd under the alias of Richard Spencer (a well-known white supremacist) and threatened to disrupt the event along with 10 others. The other organizers and I reported this threat to our schools police department and were met with rehearsed dialogue about how racism is wrong without concrete actions to support underrepresented minorities at our institution long term.

The conversation about diversity and inclusion has been ramped in some STEM graduate programs that are working with faculty and students to create a collaborative and discrimination-free environment. Many universities have expressed solidarity by producing statements addressing these racial injustices with discussions about modifying their Diversity and Inclusion Committees (DNI). However, it is not enough to have performative Diversity and Inclusion Committees that have discussionsevery once in a whileabout racial biases that have infiltrated systems of higher education. We want to see actionable items to change academic environments that negatively impact Black graduate students through policy modifications. I and many other Black graduate students have been met with many cultural competency issues from administrators who have greeted us as Dear minority graduate students in emails. White peers have made negative rebuttals and statements of hate about student organizations bringing light to the Black Lives Matter movement.

If institutions of higher learning want to be allies to Black graduate students, they need to address their own racial biases. Do not only consider our voices when you want feedback on your DNIgrants, butask us to give talks on our research or consider us for administrativepositions. Black faculty should be considered in the hiring process and tenured. Universities need to commit to increasing Black student representation in STEM PhD programs and train their staff on how to communicate with Black student recruits. When Black students enter their PhD programs, mental health resources and trained mentors should be accessible and promoted. Also, listen to Black students when we report instances of mistreatment from our PIs or superiors. Recall instances where you as a non-Black faculty member may have been complicit in this mistreatment by not reprimanding the offender for their actions. It should be mandatory for all faculty to attend training on cultural competency and courses on racism in higher learning, so they are more equipped to support Black graduate students through their journey.

We are living through a racial inequality crisis and non-Black students and academics must join in this fight and defend those who are the most vulnerable. Black students should not be the only ones fighting within their institutions for equity and justice.Werenot here for your quotas. Black students matter. Our people matter.

Paige Greenwoodis a rising 5th-year Neuroscience Doctoral Candidate at the University of Cincinnati College of Medicine and co-founder of the University of Cincinnati Science Policy Group.Paiges research focuses on the role of socioeconomic status on the behavioral and neurobiological correlates of reading for school-age children at the Cincinnati Childrens Hospital Medical Center. She became interested in science policy through her science outreach teaching elementary school children of color about neuroscience in Cincinnati Public Schools. She aims to understand how she can use her neuroscience background to advocate for STEM educational reform for marginalized and low-income communities.

Science Network Voices gives Equation readers access to the depth of expertise and broad perspective on current issues that our Science Network members bring to UCS. The views expressed in Science Network posts are those of the author alone.

Posted in: Science and Democracy Tags: Black in the ivory, Black lives matter, diversity in STEM, early career scientist

Support from UCS members make work like this possible. Will you join us? Help UCS advance independent science for a healthy environment and a safer world.

Continue reading here:
I Chose Protesting for Black Lives Matter Over Writing My PhD Dissertation - Union of Concerned Scientists

Neuroscience

The Amalgamation of Human Brain and Artificial Intelligence – Analytics Insight

The human brain has advanced over time in countering survival instincts, harnessing intellectual curiosity, and managing authoritative ordinances of nature. When humans got an idea about the dynamics of the environment, we started with our quest to replicate nature.

While the human brain discovers ways to go beyond our physical capabilities, the combination of mathematics, algorithms, computational methods, and statistical models accumulated momentum after Alan Mathison Turing built a mathematical model for biological morphogenesis, and published a seminal paper on computing intelligence.

Today, AI has developed from data models for problem-solving to artificial neural networks, a computational model predicated on the structure and functions of human biological neural networks.

The brain, customarily perceived as an organ of the human body, should be understood as a biologically predicated form of artificial intelligence (AI). This proposition was surmised by the progenitors of AI in the 1950s, though it has been generally side-lined over the course of AIs history. However, developments in both neuroscience and more conventional AI make it fascinating to consider the issue anew.

The history of neuroscience has shown both tendencies from its inception, not least in terms of the alternative functions performed by the characteristic technologies of the AI field.

Understanding the complete impacts of this distinction needs eluding from the reductionist problematic that perpetuates to haunt philosophical discussions of neurosciences aspirations as a mode of inquiry

The early prospect, which will help to build machines possessing intelligence of humans, found inspiritment in three main directions.

Firstly, proof that the functioning of the human brain and nervous system, while astonishingly perplexed from a biological perspective, is predicated on elementary all-or-nothing procedures of the type that can facilely be copied by digital electronic circuits.

Secondly, the growth of symbolic logic and formal languages that are able to communicate immense components of higher mathematics, recommending that all human reasoning might be ultimately abbreviated to similar manipulating strings of symbols according to sets of rules. Such formal operations can probably easily be imitated by a digital computer.

Thirdly, the outlook of creating faster electronic calculating devices. With regard to this, developments since the 1950s have rarely been saddening. The density of switching elements of todays microchips surpasses that of neurons in the brain.

Artificial intelligence makes industrial machines and equipment precise, credible and self-healing, making strides calibrated performance imitating human action. AI incorporates robotic controls, vision-based sensing, and geospatial systems in order to automate advanced frameworks. It improves disease detection and prevention along with its treatment, amplifies engineering systems and handles self-organizing supply chains.

We, humans, are dependent on machines for decision-making for various processes like underwriting, recruitment, fraud detection, maintenance, etc. Real Core Energy deploys machine learning that assesses production as well as performance factors to better conduct oil drilling operations and investment decisions.

Though artificial intelligence has become indispensable in almost all fields today, the presiding approaches to artificial intelligence are based in false conceptions about the nature of the mind and of the brain as a biological organ.

Sadly, the superficial models of the brain and mind, which were the initial Kickstarter of artificial intelligence, have now become the paradigm for everything called cognitive science, as well as a huge part of neurobiology. It has become a standard protocol to levy methods, concepts, models and vocabulary from the domain of artificial intelligence, computer science onto the research of the brain and the mind. It is difficult to discover a scientific paper on these subjects which does not contain terms like computing, processing, circuits, storage and retrieval of information, encoding decoding etc.

Computational neuroscience connects human intelligence and artificial intelligence by developing theoretical models of the human brain for multiple studies on its functions, including vision, motion, sensory control, and learning.

Studies in human cognition are uncovering a deeper comprehension of our nervous system and its compound processing abilities. Models that provide high-level insights into memory, data processing, and speech/object recognition are simultaneously reshaping AI.

The integration of human intelligence with artificial intelligence will evolve computers into superhumans or humanoids that go far beyond human abilities. However, it needs computing models that combine visual and natural language processing, just how the brain functions, for comprehensive communication.

Neuroscience has made significant contributions to strengthen AI research and gain its increasingly important relevance. In planning for the future amalgamation of the two fields, it is essential to value that the past contributions of neuroscience to AI have hardly consisted of a simple shift of complete solutions which can be simply re-implemented in machines. Rather, neuroscience has often been useful in a precise way, facilitating algorithmic-level questions about qualities of animal learning and intelligence of interest to AI researchers and offering initial drives toward applicable mechanisms.

Excerpt from:
The Amalgamation of Human Brain and Artificial Intelligence - Analytics Insight